TrialBritish journal of pharmacology2010

Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.

D De Forni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.